Comparison of immunohistochemical (IHC) staining for BerEp4 and MOC31 in Bowen Disease (BD)
Abstract Introduction/Objective Ber-EP4 and MOC31 are antibodies that target the epithelial cell adhesion molecule (Ep- CAM). In dermatopathology, BerEP4 IHC is classically used to differentiate between basal cell carcinoma (positive) and primary squamous cell carcinoma of the skin (negative). BerEP...
Gespeichert in:
| Veröffentlicht in: | American journal of clinical pathology 2023-11, Vol.160 (Supplement_1), p.S26-S26 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S26 |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | S26 |
| container_title | American journal of clinical pathology |
| container_volume | 160 |
| creator | Brudnik, R Toosi, P Barklow, T A Shurbaji, M S Youngberg, G A |
| description | Abstract
Introduction/Objective
Ber-EP4 and MOC31 are antibodies that target the epithelial cell adhesion molecule (Ep- CAM). In dermatopathology, BerEP4 IHC is classically used to differentiate between basal cell carcinoma (positive) and primary squamous cell carcinoma of the skin (negative). BerEP4 also stains pagetoid tumor cells in Paget Disease (PD), and can be used as part of a panel to assist in differentiating Paget Disease (positive) and Bowen Disease (presumed negative). However, a published abstract reported the unexpected finding that some cases of BD can stain variably positive for BerEP4, a potential pitfall. This finding was subsequently reported in several publications. Recently, MOC-31 has been proposed to be superior to Ber-Ep4 for use in Mohs surgery on basal cell carcinoma. We investigated whether MOC-31 might also show less positivity than Ber-Ep4 in BD, which would be helpful in the context of BD vs. PD.
Methods/Case Report
Biopsy samples from 20 cases of Bowen Disease were examined immunohistochemically with BerEP4 and MOC31.
Results (if a Case Study enter NA)
In Bowen Disease, we found significant BerEP4 positivity (14/20) compared to MOC31 (5/20).
Conclusion
MOC31 shows less frequent staining of BD than Ber-Ep4, which enhances its utility in a BD vs. PD panel. |
| doi_str_mv | 10.1093/ajcp/aqad150.058 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2955227143</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ajcp/aqad150.058</oup_id><sourcerecordid>2955227143</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1478-47c78db057a2d22a1ea3f5b3fa168d51cde6bd3797e9a230112739d7f53801ff3</originalsourceid><addsrcrecordid>eNqFkMFPwjAchRujiYjePTbxAjGD_tqNbkcZKCQYLnry0JS1lRLWjpbF-N87AndP7_K995IPoUcgIyAFG8td1YzlQSrIyIhk-RXqQZGyhHNKr1GPEEKTAji7RXcx7ggBmpO0h75KXzcy2Ogd9gbbum6d39p49NVW17aSezxYLsohjkdpnXXf2PiApzrMmxRLp_D7umSArcNT_6MdntmoZdR4MJ0N79GNkfuoHy7ZR5-v849ykazWb8vyZZVUkPI8SXnFc7UhGZdUUSpBS2ayDTMSJrnKoFJ6slGMF1wXkjICQDkrFDcZywkYw_ro6bzbBH9odTyKnW-D6y4FLbKMUg4p6yhypqrgYwzaiCbYWoZfAUScFIqTQnFRKDqFXeX5XPFt8z_9B_Qbcck</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2955227143</pqid></control><display><type>article</type><title>Comparison of immunohistochemical (IHC) staining for BerEp4 and MOC31 in Bowen Disease (BD)</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Brudnik, R ; Toosi, P ; Barklow, T A ; Shurbaji, M S ; Youngberg, G A</creator><creatorcontrib>Brudnik, R ; Toosi, P ; Barklow, T A ; Shurbaji, M S ; Youngberg, G A</creatorcontrib><description>Abstract
Introduction/Objective
Ber-EP4 and MOC31 are antibodies that target the epithelial cell adhesion molecule (Ep- CAM). In dermatopathology, BerEP4 IHC is classically used to differentiate between basal cell carcinoma (positive) and primary squamous cell carcinoma of the skin (negative). BerEP4 also stains pagetoid tumor cells in Paget Disease (PD), and can be used as part of a panel to assist in differentiating Paget Disease (positive) and Bowen Disease (presumed negative). However, a published abstract reported the unexpected finding that some cases of BD can stain variably positive for BerEP4, a potential pitfall. This finding was subsequently reported in several publications. Recently, MOC-31 has been proposed to be superior to Ber-Ep4 for use in Mohs surgery on basal cell carcinoma. We investigated whether MOC-31 might also show less positivity than Ber-Ep4 in BD, which would be helpful in the context of BD vs. PD.
Methods/Case Report
Biopsy samples from 20 cases of Bowen Disease were examined immunohistochemically with BerEP4 and MOC31.
Results (if a Case Study enter NA)
In Bowen Disease, we found significant BerEP4 positivity (14/20) compared to MOC31 (5/20).
Conclusion
MOC31 shows less frequent staining of BD than Ber-Ep4, which enhances its utility in a BD vs. PD panel.</description><identifier>ISSN: 0002-9173</identifier><identifier>EISSN: 1943-7722</identifier><identifier>DOI: 10.1093/ajcp/aqad150.058</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Basal cell carcinoma ; Biopsy ; Cancer ; Cell adhesion molecules ; Cell differentiation ; Epithelial cells ; Skin cancer ; Squamous cell carcinoma ; Tumor cells</subject><ispartof>American journal of clinical pathology, 2023-11, Vol.160 (Supplement_1), p.S26-S26</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2023</rights><rights>The Author(s) 2023. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1578,27901,27902</link.rule.ids></links><search><creatorcontrib>Brudnik, R</creatorcontrib><creatorcontrib>Toosi, P</creatorcontrib><creatorcontrib>Barklow, T A</creatorcontrib><creatorcontrib>Shurbaji, M S</creatorcontrib><creatorcontrib>Youngberg, G A</creatorcontrib><title>Comparison of immunohistochemical (IHC) staining for BerEp4 and MOC31 in Bowen Disease (BD)</title><title>American journal of clinical pathology</title><description>Abstract
Introduction/Objective
Ber-EP4 and MOC31 are antibodies that target the epithelial cell adhesion molecule (Ep- CAM). In dermatopathology, BerEP4 IHC is classically used to differentiate between basal cell carcinoma (positive) and primary squamous cell carcinoma of the skin (negative). BerEP4 also stains pagetoid tumor cells in Paget Disease (PD), and can be used as part of a panel to assist in differentiating Paget Disease (positive) and Bowen Disease (presumed negative). However, a published abstract reported the unexpected finding that some cases of BD can stain variably positive for BerEP4, a potential pitfall. This finding was subsequently reported in several publications. Recently, MOC-31 has been proposed to be superior to Ber-Ep4 for use in Mohs surgery on basal cell carcinoma. We investigated whether MOC-31 might also show less positivity than Ber-Ep4 in BD, which would be helpful in the context of BD vs. PD.
Methods/Case Report
Biopsy samples from 20 cases of Bowen Disease were examined immunohistochemically with BerEP4 and MOC31.
Results (if a Case Study enter NA)
In Bowen Disease, we found significant BerEP4 positivity (14/20) compared to MOC31 (5/20).
Conclusion
MOC31 shows less frequent staining of BD than Ber-Ep4, which enhances its utility in a BD vs. PD panel.</description><subject>Basal cell carcinoma</subject><subject>Biopsy</subject><subject>Cancer</subject><subject>Cell adhesion molecules</subject><subject>Cell differentiation</subject><subject>Epithelial cells</subject><subject>Skin cancer</subject><subject>Squamous cell carcinoma</subject><subject>Tumor cells</subject><issn>0002-9173</issn><issn>1943-7722</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqFkMFPwjAchRujiYjePTbxAjGD_tqNbkcZKCQYLnry0JS1lRLWjpbF-N87AndP7_K995IPoUcgIyAFG8td1YzlQSrIyIhk-RXqQZGyhHNKr1GPEEKTAji7RXcx7ggBmpO0h75KXzcy2Ogd9gbbum6d39p49NVW17aSezxYLsohjkdpnXXf2PiApzrMmxRLp_D7umSArcNT_6MdntmoZdR4MJ0N79GNkfuoHy7ZR5-v849ykazWb8vyZZVUkPI8SXnFc7UhGZdUUSpBS2ayDTMSJrnKoFJ6slGMF1wXkjICQDkrFDcZywkYw_ro6bzbBH9odTyKnW-D6y4FLbKMUg4p6yhypqrgYwzaiCbYWoZfAUScFIqTQnFRKDqFXeX5XPFt8z_9B_Qbcck</recordid><startdate>20231129</startdate><enddate>20231129</enddate><creator>Brudnik, R</creator><creator>Toosi, P</creator><creator>Barklow, T A</creator><creator>Shurbaji, M S</creator><creator>Youngberg, G A</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20231129</creationdate><title>Comparison of immunohistochemical (IHC) staining for BerEp4 and MOC31 in Bowen Disease (BD)</title><author>Brudnik, R ; Toosi, P ; Barklow, T A ; Shurbaji, M S ; Youngberg, G A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1478-47c78db057a2d22a1ea3f5b3fa168d51cde6bd3797e9a230112739d7f53801ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Basal cell carcinoma</topic><topic>Biopsy</topic><topic>Cancer</topic><topic>Cell adhesion molecules</topic><topic>Cell differentiation</topic><topic>Epithelial cells</topic><topic>Skin cancer</topic><topic>Squamous cell carcinoma</topic><topic>Tumor cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brudnik, R</creatorcontrib><creatorcontrib>Toosi, P</creatorcontrib><creatorcontrib>Barklow, T A</creatorcontrib><creatorcontrib>Shurbaji, M S</creatorcontrib><creatorcontrib>Youngberg, G A</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>American journal of clinical pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brudnik, R</au><au>Toosi, P</au><au>Barklow, T A</au><au>Shurbaji, M S</au><au>Youngberg, G A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of immunohistochemical (IHC) staining for BerEp4 and MOC31 in Bowen Disease (BD)</atitle><jtitle>American journal of clinical pathology</jtitle><date>2023-11-29</date><risdate>2023</risdate><volume>160</volume><issue>Supplement_1</issue><spage>S26</spage><epage>S26</epage><pages>S26-S26</pages><issn>0002-9173</issn><eissn>1943-7722</eissn><abstract>Abstract
Introduction/Objective
Ber-EP4 and MOC31 are antibodies that target the epithelial cell adhesion molecule (Ep- CAM). In dermatopathology, BerEP4 IHC is classically used to differentiate between basal cell carcinoma (positive) and primary squamous cell carcinoma of the skin (negative). BerEP4 also stains pagetoid tumor cells in Paget Disease (PD), and can be used as part of a panel to assist in differentiating Paget Disease (positive) and Bowen Disease (presumed negative). However, a published abstract reported the unexpected finding that some cases of BD can stain variably positive for BerEP4, a potential pitfall. This finding was subsequently reported in several publications. Recently, MOC-31 has been proposed to be superior to Ber-Ep4 for use in Mohs surgery on basal cell carcinoma. We investigated whether MOC-31 might also show less positivity than Ber-Ep4 in BD, which would be helpful in the context of BD vs. PD.
Methods/Case Report
Biopsy samples from 20 cases of Bowen Disease were examined immunohistochemically with BerEP4 and MOC31.
Results (if a Case Study enter NA)
In Bowen Disease, we found significant BerEP4 positivity (14/20) compared to MOC31 (5/20).
Conclusion
MOC31 shows less frequent staining of BD than Ber-Ep4, which enhances its utility in a BD vs. PD panel.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/ajcp/aqad150.058</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9173 |
| ispartof | American journal of clinical pathology, 2023-11, Vol.160 (Supplement_1), p.S26-S26 |
| issn | 0002-9173 1943-7722 |
| language | eng |
| recordid | cdi_proquest_journals_2955227143 |
| source | Oxford University Press Journals All Titles (1996-Current); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Basal cell carcinoma Biopsy Cancer Cell adhesion molecules Cell differentiation Epithelial cells Skin cancer Squamous cell carcinoma Tumor cells |
| title | Comparison of immunohistochemical (IHC) staining for BerEp4 and MOC31 in Bowen Disease (BD) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T23%3A04%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20immunohistochemical%20(IHC)%20staining%20for%20BerEp4%20and%20MOC31%20in%20Bowen%20Disease%20(BD)&rft.jtitle=American%20journal%20of%20clinical%20pathology&rft.au=Brudnik,%20R&rft.date=2023-11-29&rft.volume=160&rft.issue=Supplement_1&rft.spage=S26&rft.epage=S26&rft.pages=S26-S26&rft.issn=0002-9173&rft.eissn=1943-7722&rft_id=info:doi/10.1093/ajcp/aqad150.058&rft_dat=%3Cproquest_cross%3E2955227143%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2955227143&rft_id=info:pmid/&rft_oup_id=10.1093/ajcp/aqad150.058&rfr_iscdi=true |